Effect of agents that alter cyclic AMP on archidonate-induced platelet aggregation in the dog

Blood (Impact Factor: 10.45). 06/1980; 55(5):722-9.
Source: PubMed


Recent studies in our laboratory demonstrated that 30% of normal mongrel dogs have platelets that aggregate when stirred with sodium arachidonate (ASP), while the majority have platelets that do not aggregate under similar circumstances (AIP). In the current study, we confirmed previous observations that indicated that AIP formed aggregating products of prostaglandin metabolism (endoperoxides and/or thromboxane A2) when stirred with sodium arachidonate. We also determined that the difference between ASP and AIP was attributable to the platelets rather than the plasma. To further define the mechanism responsible for the difference between ASP and AIP, we studied the response of dog platelets to agents known to alter platelet cyclic AMP, and we measured platelet cyclic AMP. Radioimmunoassay of cyclic AMP in platelet-rich plasma (PRP) and in washed platelets demonstrated no differences between unstimulated ASP and AIP. However, agents that lower elevated platelet cyclic AMP (epinephrine, norepinephrine, adenosine diphosphate, serotonin and low concentrations of prostaglandin E2) uniformly converted AIP to ASP. Agents that elevate platelet cyclic AMP (prostaglandins E1, D2, I2, theophylline and dibutyryl cyclic AMP) uniformly converted ASP to AIP. The addition of epinephrine, following prostaglandin I2 (PGI2) restored the ability of ASP to aggregate when stirred with sodium arachidonate. In vitro PGI2 (0.14-2.1 nM) converted ASP to AIP without inhibiting adenosine diphosphate (ADP) or collagen-induced aggregation, thereby duplicating the behavior of naturally occurring AIP. PGI2 infusions produced the same result in vivo. The results of these studies suggest that cyclic AMP plays an important role in regulating the response of dog platelets to the aggregating products of prostaglandin metabolism. AIP have a cyclic AMP-dependent mechanism that modulates their response to the aggregating products of prostaglandin metabolism that is different from ASP and human platelets We postulate that AIP retain the effects of in vivo elevation of platelet cyclic AMP stimulated by exposure to PGI2. The mechanism by which this occurs is uncertain.

Download full-text


Available from: Gundu H R Rao,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prostacyclin (PGI2) is a powerful inhibitor of platelet function and recent studies have indicated that it can dissociate aggregated platelets in vivo. The present investigation has evaluated the mechanism involved in the dissociation of ADP aggregated platelets by PGI2, the influence of epinephrine on the process of PGI2 mediated disaggregation, and effects of the catecholamine on the refractory state of PGI2 dispersed cells. Dissociation of ADP aggregates by PGI2 was concentration and time dependent, caused complete disappearance of sensitive platelet clumps and restored platelet discoid form. The dispersed platelets were refractory to further stimulation by ADP, thrombin, arachidonate or the calcium ionophore, A23187. Measurement of cAMP revealed no change in control levels after aggregation by ADP, but a sharp increase during and after dissociation by PGI2. Epinephrine added to ADP aggregates before or after PGI2 blocked disaggregation, or stopped dissociation if already in progress, and caused a rapid fall in the high levels of cAMP stimulated by PGI2. Agents to which PGI2 dissociated platelets were refractory, including ADP, arachidonate and A23187 caused no lowering of elevated cAMP levels. Reduction of high levels of cAMP in PGI2 dispersed platelets by epinephrine did not result in reaggregation. However, epinephrine addition to refractory platelets restored in large measure their sensitivity to aggregation by arachidonate, thrombin, ADP and A23187.
    Prostaglandines and Medicine 07/1980; 4(6):385-97. DOI:10.1016/0161-4630(80)90047-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Calmodulin has been shown to activate platelet phospholipase A2 and initiate the metabolism of arachidonic acid. Trifluoperazine (stelazine), an agent which selectively binds calmodulin, inhibits phospholipase activity induced by calcium. We have evaluated the effect of this agent on the aggregation, disaggregation and reaggregation of human platelets. Results of our study have shown that stelazine is a selective inhibitor of the second wave response of platelets to the stimulation of agonists. The compound causes dissociation of aggregated platelet clumps and induces a refractory state in dispersed cells. Epinephrine reverses the refractory state and potentiates the response of dissociated cells to the action of thrombin, arachidonate and ionophore A23187. Stelazine elevates cAMP levels to some extent and inhibits release of labeled arachidonic acid from platelet membranes in response to thrombin induced stimulation. Epinephrine may correct stelazine induced inhibition by acting through α-adrenergic mechanism, by inducing changes in membrane permeability to calcium, by releasing membrane associated calcium or by directly promoting deacylation of phospholipids.
    Prostaglandines and Medicine 09/1980; 5(3-5):221-234. DOI:10.1016/S0161-4630(80)80007-3

  • Vox Sanguinis 02/1981; 40 Suppl 1(s1):123-4. DOI:10.1111/j.1423-0410.1981.tb00748.x · 2.80 Impact Factor
Show more